Veru announces positive phase 1b/2 clinical study update for sabizabulin (veru-111) in men with metastatic castration resistant prostate cancer presented at the 2021 asco annual meeting

-- sabizabulin, an oral selective cytoskeleton disruptor, demonstrated good safety, significant evidence of antitumor efficacy, and that chronic administration is feasible in ongoing phase 1b/2 study of 80 men -- -- phase 3 veracity study to evaluate sabizabulin treatment in men who have metastatic castration prostate cancer and have also progressed following at least one androgen receptor targeting agent planned to start this month --
VERU Ratings Summary
VERU Quant Ranking